Post-Marketing Clinical Study of Mirabegron-Add-on Therapy With Mirabegron in Patients With Overactive Bladder Under Treatment With Solifenacin

Trial Profile

Post-Marketing Clinical Study of Mirabegron-Add-on Therapy With Mirabegron in Patients With Overactive Bladder Under Treatment With Solifenacin

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Mirabegron (Primary) ; Solifenacin
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 24 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top